SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

KILITCH DRUGS (INDIA)

BSE: 524500 29 Jun 2025
Healthcare
₹ 432.8
Kilitch Drugs (I) Ltd. specializes in Pharmaceuticals within the Healthcare sector.

KILITCH DRUGS (INDIA) - Share Price & Details

Market Cap
₹694.0
High /Low
500.0 / 271.0
Stock P/E
27.8
Book Value
₹126.0
Dividend Yield
0.0
ROCE
17.3
ROE
₹13.2
Face Value
10.0
PEG Ratio
0.17
EVEBITDA
₹17.2
Debt
49.4
CMP / FCF
-56.1
Debt to equity
₹0.24
NP Ann
24.9
High price all time
500.0
Piotroski score
₹7.0
Graham Number
217.0
No. Eq. Shares
1.61
Net CF
₹-9.16
Net profit
24.9
Price to book value
3.43
Interest Coverage
₹7.84
Low price all time
16.0
Industry PE
32.0
Reserves
₹186
Free Cash Flow
₹-29.3

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
KILITCH DRUGS (INDIA) LTD.586.29113.74563.047.07694.027.8
IND-SWIFT LABORATORIES LTD.NANANANA6658.04
NGL FINE-CHEM LTD.922.27-5.21930.17-0.8461829.3

Peer Comparison Chart


About KILITCH DRUGS (INDIA)

Kilitch Drugs (I) Ltd., with Security Code 524500, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Kilitch Drugs Faces Investor Sentiment Shift Amid Declining Trading Activity

(01 Jun 2025)
Kilitch Drugs (India) Ltd has faced notable trading activity, hitting its lower circuit limit with a significant decline in stock price.
Read more →

Impressive Earnings May Not Tell The Whole Story For Kilitch Drugs (India) (NSE:KILITCH)

(27 May 2025)
Kilitch Drugs (India) Limited's ( NSE:KILITCH ) stock was strong after they recently reported robust earnings. However...
Read more →

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr

(26 May 2025)
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25.
Read more →

Kilitch Drugs Limited Q4FY25 PAT registers 212% YoY remarkable growth and Revenue from operations rises by 44 % on Standalone Basis

(23 May 2025)
Kilitch Drugs Limited, BSE and NSE listed, a leading pharmaceutical company specializing in the manufacturing and distribution of...
Read more →

Kilitch Drugs (India) (NSE:KILITCH) stock performs better than its underlying earnings growth over last five years

(22 May 2025)
For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...
Read more →

Kilitch Drugs (India) consolidated net profit rises 189.69% in the March 2025 quarter

(21 May 2025)
Sales rise 36.61% to Rs 61.23 crore. Net profit of Kilitch Drugs (India) rose 189.69% to Rs 10.40 crore in the quarter ended March 2025 as...
Read more →